In a significant development for the infection management medical device sector, Novo Holdings has announced a strategic investment in Biocomposites, partnering with existing majority shareholder TA Associates to drive the company's next phase of growth.
The transaction establishes shared control between Novo Holdings and TA Associates, with both firms committed to accelerating Biocomposites' expansion in the global medical device market. TA Associates, which has held a majority stake since 2017, will reinvest alongside Novo Holdings, while Biocomposites' management team maintains their position in the company.
Track Record of Innovation and Growth
Biocomposites, headquartered in Keele, United Kingdom, has established itself as a pioneer in infection management solutions for bone and soft tissue. The company's flagship product, STIMULAN, represents a breakthrough in antibiotic delivery technology as the only calcium matrix carrier platform approved to transport antibiotics to both infected and non-infected sites.
Under TA Associates' stewardship since 2017, Biocomposites has achieved remarkable growth metrics:
- Revenue increased threefold
- Successfully expanded geographical presence
- Diversified product portfolio
- Completed two strategic acquisitions
- Extended reach into new therapeutic areas
Market Presence and Clinical Impact
The company's advanced solutions currently serve healthcare providers in more than 100 countries, with their products being utilized in over one million procedures annually. Their technology spans multiple specialties, including:
- Musculoskeletal infection
- Orthopedics
- Trauma
- Spine
- Foot and ankle
- Sports injuries
Strategic Vision and Leadership Perspectives
Henrik Kjær Hansen, Senior Partner at Novo Holdings, emphasized the strategic alignment between Biocomposites' infection management solutions and Novo Holdings' life sciences portfolio. "With our deep expertise in life sciences and extensive global network, we look forward to supporting Biocomposites in expanding its international footprint," Hansen stated.
Michael Harris, Biocomposites' CEO, expressed enthusiasm about the new partnership: "This investment is a significant validation of Biocomposites' achievements so far and our future prospects for growth. With the combined expertise and support of these two leading global healthcare investors, we believe we are well positioned to deliver on our commitment to bring ever more innovative products for use in infection management to more people worldwide."
Future Growth Strategy
The partnership aims to:
- Deepen global market penetration
- Advance product innovation pipeline
- Scale delivery of infection management solutions
- Enhance patient outcomes worldwide
Birker Bahnsen, Managing Director at TA, highlighted Biocomposites' evolution: "The Company has consistently demonstrated its ability to scale internationally while building out a diversified product portfolio that aligns with growing market demand and meets evolving patient needs."
While financial terms remain undisclosed, the transaction represents a significant milestone in Biocomposites' journey to transform infection management in medical procedures globally.
